NASDAQ:ARWR 25 November 2025 - 9 February 2026

New York, Feb 9, 2026, 15:05 EST — Regular session Arrowhead Pharmaceuticals slipped roughly 0.7% to $64.10 Monday afternoon, following a session that saw the stock range from $61.48 up to $66.17.

NEW YORK, December 30, 2025, 13:47 ET — Regular session Arrowhead Pharmaceuticals Inc shares were down 3.6% at $67.09 at 1:47 p.m. ET on Tuesday, after trading between $65.94 and $69.95.

Arrowhead Pharmaceuticals, Inc. is seeing a sharp pullback in Tuesday trading, with shares recently changing hands around $62—down roughly 9% from the prior close—after hitting an intraday low near $59.76. That drop may look dramatic in isolation, but it’s landing on top of an unusually eventful stretch for the RNA interference biotech: Arrowhead just transitioned into a commercial-stage story after its first FDA approval, picked up an FDA Breakthrough Therapy designation for a follow-on indication, and kicked off a new Alzheimer’s-related clinical program—three ingredients that tend to increase both upside narratives and day-to-day volatility in biotech stocks. Reuters+2Arrowhead Pharmaceuticals, Inc.+2

Arrowhead Pharmaceuticals, Inc. is ending 2025 in rare biotech air. The RNA interference specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a new Alzheimer’s disease trial — all while its share price hovers near record highs. Arrowhead Pharmaceuticals, Inc.+2Arrowhead Pharmaceuticals+2 As of intraday trading on December 9, 2025, Arrowhead Pharmaceuticals stock trades around $69 per share, giving the company a market value in the $9–9.5 billion range. That’s up dramatically from under $10 per share at its 52‑week low, and represents a triple‑digit gain over the past year and roughly 260–270% year‑to‑date, depending on the data source. Yahoo Finance+2Investing.com+2